Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort.

导出 LinkOut

翻译打印收藏纠错

作者： Gavin,Giovannoni ^[1] ; Alexey,Boyko ^[2] ; Jorge,Correale ^[3] ; Gilles,Edan ^[4] ; Mark S,Freedman ^[5] ; Xavier,Montalban ^[6] ; Kottil,Rammohan ^[7] ; Dusan,Stefoski ^[8] ; Bassem,Yamout ^[9] ; Thomas,Leist ^[10] ; Aida,Aydemir ^[11] ; Laszlo,Borsi ^[12] ; Elisabetta,Verdun di Cantogno ^[11]

作者单位： Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK. ^[1] Department of Neurology, Pirogov Russian National Research Medical University, Neurosurgery and Medical Genetics, Federal Center of Brain Research and Neurotechnologies, Moscow, Russia. ^[2] Department of Neurology, FLENI Institute, Buenos Aires, Argentina. ^[3] Department of Neurology, University Hospital of Rennes, Rennes, France. ^[4] Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada. ^[5] Department of Neurology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain. ^[6] University of Miami School of Medicine, MS Research Center, Miami, FL, USA. ^[7] Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA. ^[8] Neurology Institute, Harley Street Medical Center, Abu Dhabi, UAE; American University of Beirut Medical Center, Beirut, Lebanon. ^[9] Division of Clinical Neuroimmunology, Jefferson University, Comprehensive MS Center, Philadelphia, PA, USA. ^[10] EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, MA, USA. ^[11] Merck Healthcare KGaA, Darmstadt, Germany. ^[12]

关键词 Cladribine tablets Expanded Disability Status Scale disability disease-modifying therapy first clinical demyelinating event multiple sclerosis